In Regard to Buszek et  al

The recent report by Buszek et  al reassuringly reveals equivalent 5-year overall survival among older patients with breast cancer who have undergone lumpectomy and are receiving adjuvant monotherapy, whether with radiation therapy (RT) or hormone therapy (HT).1 This contribution is consistent with prior efforts in favorable sub populations for which disease-specific outcomes are excellent, remaining life expectancy is limited, and the survival benefit of any adjuvant treatment remains notoriously elusive.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Comment Source Type: research

Related Links:

Women whose periods stop before the age of 40 are at greater risk of diabetes, heart disease, strokes, asthma and breast cancer, the study found. The UK menopause average is 51.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Source: Archives of Physiology and Biochemistry - Category: Physiology Authors: Source Type: research
ConclusionsA majority of IBC patients in our study presented with node-positive disease, and for those presenting with cN2-3 disease, more extensive axillary surgery is potentially associated with improved survival. For cN0 patients, however, more extensive axillary surgery was not associated with a survival benefit, suggesting an opportunity for more personalized care.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionOverall, these guidelines provide consistent recommendations on who should receive breast reconstruction education, who is a candidate for postmastectomy breast reconstruction, and the appropriate timing of reconstruction and extent of mastectomy. Future updates from all should focus on expanding to include alloplastic and autologous forms of reconstruction and should include a broad scope of relevant questions.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Conclusion: S-ketamine is more effective for reducing POD for breast cancer patients. PMID: 31948296 [PubMed - as supplied by publisher]
Source: Journal of Investigative Surgery - Category: Surgery Tags: J Invest Surg Source Type: research
Authors: Pereira JX, Dos Santos SN, Pereira TC, Cabanel M, Chammas R, de Oliveira FL, Bernardes ES, El-Cheikh MC Abstract Galectin-3 (Gal-3) is a multifunctional β-galactoside-binding lectin that once synthesized is expressed in the nucleus, cytoplasm, cell surface, and extracellular environment. Gal-3 plays an important role in breast cancer tumors due to its ability to promote interactions between cell-cell and cell-extracellular matrix (ECM) elements, increasing tumor survival and metastatic dissemination. Still, the mechanism by which Gal-3 interferes with tumor cell migration and metastasis formation is c...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
Authors: Cao K, Zhao B, Li XT, Li YL, Sun YS Abstract Objectives: MRI is the standard imaging method in evaluating treatment response of breast cancer after neoadjuvant therapy (NAT), while identification of pathologic complete response (pCR) remains challenging. Texture analysis (TA) on post-NAT dynamic contrast-enhanced (DCE) MRI was explored to assess the existence of pCR in mass-like cancer. Materials and Methods: A primary cohort of 112 consecutive patients (40 pCR and 72 non-pCR) with mass-like breast cancers who received preoperative NAT were retrospectively enrolled. On post-NAT MRI, volumes of the resi...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
Authors: Batoo S, Bayraktar S, Al-Hattab E, Basu S, Okuno S, Glück S Abstract With the introduction of anthracycline-based regimens, 5-year survival rates have significantly improved in patients with early-stage breast cancer. With the addition of trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), improvements in overall survival have been observed among patients with advanced HER2-positive disease. Subsequently, lapatinib, an orally bioavailable small molecule dual HER2- and EGFR/HER1-specific tyrosine kinase inhibitor, received Food and Drug Administration (FDA)...
Source: Journal of Carcinogenesis - Category: Cancer & Oncology Tags: J Carcinog Source Type: research
Publication date: Available online 18 January 2020Source: Redox BiologyAuthor(s): Mohamad Assi, Suzanne Dufresne, Amélie RébillardAbstractIn this paper of the special issue dedicated for the Olympics 2020, we put the light on an exciting facet of exercise-oncology, which may still be unknown to some audience. Accumulating convincing evidences show that exercise reduces cancer progression and recurrence mainly in colon and breast cancer patients. Interestingly, the positive effects of exercise on cancer outcomes were mainly observed when patients practiced vigorous exercise of 6 METs or more. At the molecular ...
Source: Redox Biology - Category: Biology Source Type: research
These results highlight the increased prevalence of cardiovascular risk factors in these patients, and the need for personalized risk assessments for cardiac complications following cardiotoxic therapies.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
More News: Biology | Breast Cancer | Breast Lumpectomy | Cancer | Cancer & Oncology | Hormonal Therapy | Hormones | Lumpectomy | Physics | Radiation Therapy | Radiology